CF@P possesses antioxidant/anti-inflammatory properties by inhibiting pyruvate dehydrogenase kinase 4 (PDK4) and exhibited promising capabilities in T1-MRI and photoacoustic imaging for AKI management [251]. The gene discussed is PDK4; the disease is acute kidney injury.